Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Concentrated Amylopectinchromium Blend

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07402382Not ApplicableRecruitingPrimary

Effects of Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose in Peri/Post-Menopausal Women

NCT07089979Not ApplicableCompletedPrimary

Effectiveness of Glunovo Real-Time Continuous Glucose Monitoring in Adults With Type 2 Diabetes

Showing all 2 trials

Research Network

Common Treatments

  • Concentrated Amylopectinchromium Blend1
  • Amylopectinchromium Blend1
  • Bgmeter1
  • Glunovo Cgm Device1

Active Sponsors

  • University of Milan1
  • Nutrition 21, Inc.1
  • The Center for Applied Health Sciences, LLC1

Top Investigators

Related Conditions

  • Whole Body Protein Metabolism1
  • Perimenopausal Women1
  • Postmenopause1

Activity Timeline